Lomitapide News
Lomitapide currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Lomitapide with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Lojuxta is indicated as an adjunct to a low?fat diet and other lipid?lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial...
- Evidence level: L5
- Predicted indications (20):
- marcothrombocytopenia with mitral valve insufficiency (99.9%)
- hereditary thrombocytopenia with normal platelets (99.9%)
- dense granule disease (99.9%)
- transient neonatal thrombocytopenia (99.9%)
- homozygous familial hypercholesterolemia (99.9%)
- thrombocytopenia (99.9%)
- primary release disorder of platelets (99.8%)
- pseudo-von Willebrand disease (99.8%)
- Glanzmann thrombasthenia (99.8%)
- hyperlipoproteinemia (99.7%)
- platelet storage pool deficiency (99.5%)
- hyperlipidemia, familial combined, LPL related (99.5%)
- primary hyperoxaluria (99.0%)
- Scott syndrome (98.7%)
- obsolete familial combined hyperlipidemia (98.6%)
- fibroma of prostate (98.5%)
- fetal and neonatal alloimmune thrombocytopenia (98.4%)
- cholesterol-ester transfer protein deficiency (98.3%)
- benign reproductive system neoplasm (98.3%)
- prostate cancer/brain cancer susceptibility (98.2%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.